http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007144680-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6879 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2006-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007144680-A |
| titleOfInvention | ANTI-CD 16 BINDING MOLECULES |
| abstract | 1. A binding molecule having specificity for at least one antigen, wherein said at least one antigen is FcγRIIIA, and said binding molecule does not specifically bind to FcγRIIIB. ! 2. The binding molecule according to claim 1, characterized in that the specificity for FcγRIIIA is provided by the antibody or antigen-binding fragment of the antibody. ! 3. The binding molecule according to claim 2, characterized in that the specificity for FcγRIIIA is provided by an antigen-binding fragment. ! 4. The binding molecule according to claim 3, characterized in that the antigen binding fragment is selected from the group consisting of immunoglobulin light chain, immunoglobulin heavy chain, VH domain, VL domain, Fv, Fab, di-Fab, Fab ', F (ab' ) 2, scFv and CDR (hypervariable region). ! 5. A binding molecule according to any one of claims 2 to 4, characterized in that the antibody or antigen binding fragment comprises at least one human hypervariable region. ! 6. The binding molecule according to claim 5, characterized in that the hypervariable region has an amino acid sequence selected from the group consisting of SEQ ID Nos. 20, 23, 26, 29, 33, 34, 21, 24, 27, 30, 31 , 35, 22, 25, 28, 32, 17, 18 and 19.! 7. A binding molecule according to any one of claims 1 to 4 or 6, characterized in that the antibody or antigen binding fragment comprises three human light chain hypervariable regions (CDRs). ! 8. The binding molecule according to claim 7, characterized in that the human light chain CDR1 sequence is selected from the group comprising SEQ ID Nos. 20, 23, 26, 29, 33 and 34, the human light chain CDR2 sequence is selected from the group comprising SEQ ID Nos. 21, 24, 27, 30, 31 and 35, and the CDR3 sequence of the human light chain is selected from the group including |
| priorityDate | 2005-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.